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Objective: Biventricular assist device support with a paracorporeal pulsatile device is known to be an efficient
bridge to recovery for patients with fulminant myocarditis–related cardiogenic shock. Whether these patients can
be as efficiently supported with femorofemoral extracorporeal membrane oxygenation remains unclear.
Methods: From 2001 to 2006, 11 patients were referred to our cardiac surgery department for fulminant myo-
carditis–related cardiogenic shock. The first 5 patients (mean age, 32 2 years) were supported with a biventric-
ular assist device (Thoratec, Pleasanton, Calif; group I), whereas the remaining patients (40  4 years) were
supported with femorofemoral extracorporeal membrane oxygenation (group II). Preimplantation probability
of death was calculated by using the APACHE II score, which was 11  9 in group I versus 24  18 in group II.
Results: One patient in each group died while receiving support. In group I the death occurred after 18 days of
support in a patient who had 45 minutes of external resuscitation before biventricular assist device implantation.
In group II a patient who remained unstable during extracorporeal membrane oxygenation was switched to a bi-
ventricular assist device 13 days later and eventually died of tamponade after 45 days. All other patients were
weaned from the device after a mean duration of support of 21  5 days in group I versus 13  4 days in group
II. At hospital discharge, the mean ejection fraction was 45% 5% in both groups, and at 6 months’ follow-up, it
was 65% and 75%, respectively, in groups I and II.
Conclusion: In our experience extracorporeal membrane oxygenation is as efficient as use of a biventricular assist
device as a bridge to recovery for patients with fulminant myocarditis–related cardiogenic shock and facilitates
renal and hepatic recovery on support.Complete recovery of myocardial function is possible after
fulminant myocarditis (FM) in the adult by using mechanical
support as a bridge to recovery.1 Acker,2 in 2001, reviewed
the literature comparing different types of mechanical sup-
port. He found that survival by bridge to transplantation or
to recovery should approach 70% and then strongly recom-
mended an aggressive approach to use of biventricular
mechanical support.
In the setup of FM, Leprince and colleagues,3 in 2003,
recommended the use of a biventricular assist device
(BIVAD) during cardiopulmonary bypass on the beating
heart. However, during the most recent years, extracorporeal
membrane oxygenation (ECMO)–extracorporal life support
was revealed as a precious cardiac support method used to
stabilize emergency patients with severe cardiac dysfunc-
tion. The first results were very encouraging, and ECMO
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source allocation. Because some of these patients had FM,
we are now able to compare the efficacy and usefulness of
ECMO versus the BIVAD in the setting of this acute disease.
MATERIALS AND METHODS
Between March 2001 and May 2006, 11 consecutive patients underwent
mechanical cardiac support for FM. Five patients (group I) received a pneu-
matic paracorporeal BIVAD (Thoratec, Pleasanton, Calif). The 6 following
patients (group II) received ECMO with the Jostra Rota Flow pump and the
Quadrox Jostra D oxygenator (Maquet Cardiopulmonary AG, Hirrlingen,
Germany). The ECMO device was implanted with femorofemoral cannula-
tion and reperfusion of the superficial femoral artery with a femoral Seldi-
cath connected in derivation on the arterial line (Figure 1).
As shown in Table 1, both groups were similar at clinical presentation.
The APACHE II score did not show any difference between both groups
(11  9 for group I vs 24  18 for group II), but there was a trend toward
a higher score in group II patients. This means that even if the difference
between groups was not significant, we observed a tendency for group II
patients to be sicker.
All BIVADs were managed as previously described.3
ECMO devices were implanted on local (for 2 patients) and general (for
2 other patients) anesthesia at La Pitie´’s cardiac surgery department. The re-
maining 2 ECMO devices were installed in a primary care hospital ICU by
the La Pitie´’s Circulatory Assistance Mobile Unit in unstable nontransfer-
able patients. Those patients were secondarily transferred on ECMO at La
Pitie´’s Hospital. Only 1 patient was admitted with an intra-aortic balloon
counterpulsation (IABCP).
ECMO hemodynamic daily evaluation includes arterial pressure wave-
form assessment of occurrence of pulsatile blood flow and mean arterialgery c January 2009
Pages et al Evolving Technology
E
TAbbreviations and Acronyms
BIVAD ¼ biventricular assist device
ECLS ¼ extracorporal life support
ECMO ¼ extracorporeal membrane oxygenation
FM ¼ fulminant myocarditis
IABCP ¼ intra-aortic balloon counterpulsation
RBCU ¼ red blood cell unit
pressure level and transthoracic echocardiography, transesophageal echo-
cardiography, or both. Pump speed is adjusted to achieve an extracorporeal
blood flow of 4 to 7 L/min. Supportive care (volume expansion, catechol-
amines, or both) is based on the results of these repeated hemodynamic
evaluations. Pharmacologic therapy (eg, intravenous immunoglobulins or
corticosteroids) to facilitate myocardial healing were never used. IABCP
was never required during assistance. Anticoagulation is achieved with
unfractionated heparin to obtain an anti-Xa activity of 0.2 to 0.5 UI/mL.
In addition, patients with platelet counts of greater than 100 Giga/L receive
100 mg of aspirin per day.
Postoperative care is performed for all patients in the intensive care unit.
Weaning of BIVAD is performed as described by Slaughter et al.4
Concerning weaning of ECMO, myocardial recovery is assessed on the
basis of several criteria: recovery of pulsatile blood flow, demonstration of
a significant systolic heart function on echocardiographic analysis, and
acceptable blood oxygenation. In these conditions an ECMO weaning trial
is undertaken by progressively reducing the pump flow to less than 1.5 L/
min and then by clamping both the venous and arterial lines of the circuit.
The results of the weaning trial are considered favorable if after 2 minutes
left ventricular ejection fraction remains at greater than 35% to 40% and
aortic blood flow time-velocity integral remains greater than 14 cm; how-
ever, ECMO pump flow is always restored for another 24 hours at 1.5 L/
min. Finally, if the patient’s hemodynamic status remains stable during
this period, the ECMO device is removed.
RESULTS
Mean time of assistance from implantation to weaning
was 21  5 days in group I versus 13  4 days in group II.
One patient died in each group. In group I the patient was
a woman who underwent 45 minutes of resuscitation by
means of external cardiac massage before implantation of
the BIVAD. Death occurred after 18 days during support be-
cause of multiorgan failure. In group II the patient who was
transferred at La Pitie´ under IABCP still showed an unstable
hemodynamic status on femorofemoral ECMO. Then at day
10 she required intrathoracic ECMO implantation to pro-
duce a better flow associated with a pulmonary artery can-
nula to better unload the pulmonary vascular bed. At day
17, decreasing outflow motivated switch to a BIVAD, which
permitted recovery of hemodynamic status. Unfortunately,
she died of tamponade at day 45.
Other patients were weaned from mechanical circulatory
support and were discharged home alive. In both groups
no transplantations were required. Left ventricular function
finally improved identically in both groups: 45% at weaning
and 65% to 75% at 6 months’ follow-up.
Mean flow was 5.4 0.7 L/min (3.3 0.5 L $ min1 $ m2)
in group I versus 4.8 0.4 L/min (2.5 0.7 L $ min1 $ m2)The Journal of Thoracic and Cin group II. However, 2 patients in group II presented with
a low outflow requiring therapeutic modifications. The first
patient described above eventually died. The second patient
with low flow had transient improvement when moving the
venous cannula, but at day 5, because of worsening of pulmo-
nary edema, images observed on chest x-ray films, and persis-
tent low flow (3550 L/min), he underwent intrathoracic
ECMO device implantation. Immediately, the patient had
a satisfactory flow at 5900 L/min for 4500 rpm and quickly
recovered his ventricular function. The ECMO device was
removed at day 13.
Figure 2 shows the evolution of plasmatic creatinine, total
bilirubin, and transaminases in both groups: there was no
significant difference before implantation; however, it is
obvious that immediately after implantation of the BIVAD,
group I patients experienced an initial phase of worsening
before improvement. On the other hand, in group II patients
implantation of ECMO was immediately followed by renal
FIGURE 1. Representation of the femorofemoral ECMO circuit. A, Arte-
rial line (using a 15F–19F cannula inserted in a common femoral artery); V,
venous line (using a 19F–23F cannula inserted in the femoral vein); R,
reperfusion of the superficial femoral artery with a femoral Seldicath
connected in derivation on an arterial line (using a 5F 11-cm-long catheter).
The A and R lines are crossed before respective arterial cannulations.
TABLE 1. Clinical presentation of BIVAD group patients (group I)
and ECMO group patients (group II)
Group I (n ¼ 5) Group II (n ¼ 6) P value
Sex (male/female) 2/3 3/3 NS
Age (y) 32  2 40  4 NS
Ejection fraction
(left ventricle)
33%  8% 18%  4% NS
Creatininemia (mg/L) 19.5  7 13.2  3 NS
Total bilirubinemia (mg/L) 8  2 23  6 NS
APACHE II score 11  9 24  18 NS
BIVAD, Biventricular assist device; ECMO, extracorporeal membrane oxygenation;
NS, not significant.ardiovascular Surgery c Volume 137, Number 1 195















































FIGURE 2. Graphics showing evolutions of renal (creatininemia, A) and hepatic (total bilirubinemia, B; aspartate aminotransferase [SGOT], C) functions
in both groups: ECMO is shown in black, and BIVAD is shown in white. D0, Day 0 after implantation; D1, D1 after implantation; D8, D8 after implantation;
W, weaning; BIVAD, biventricular assist device; ECMO, extracorporeal membrane oxygenation.and hepatic function recovery. Even transaminase values
decreased faster in group II than in group I. Moreover, this
period of adaptation with a BIVAD might explain why, con-
cerning inotropic support, the whole of group I still required
noradrenaline after 48 hours of assistance versus one third of
patients in group II.
Mean rate of red blood cell unit (RBCU) transfusion were
statistically different between groups: 22 5 RBCU per pa-
tient in group I versus 7  4 RBCU per patient in group II
(P ¼ .03). This reflects the fact that the re-exploration rate
for hemostasis was lower in the myocarditis group supported
by ECMO. Concerning infectious complications, all patients
from group I had orotracheal intubation and finally pre-
sented with pneumonia (Haemophilus influenzae was most
frequently found). Two of them had septicemia. On the
other hand, the 3 patients in group II who received ECMO
under local anesthesia (ie, without intubation) never had pul-
monary infection (only 66% of group II patients had pneu-
monia). Another patient in group II had an infection of his
cannulas. At that time, he showed a sufficient recovery to un-
dergo ECMO explantation (left ventricular ejection fraction,
40%) and was finally discharged at day 38.196 The Journal of Thoracic and Cardiovascular SurNo neurologic complications were noted in both groups.
The 1-year survival of patients weaned from BIVAD and
ECMO was 4 of 4 and 4 of 5, respectively. The patient who
died in group II committed suicide 3 months after discharge
home.
DISCUSSION
This is the first comparative study between ECMO and
a BIVAD in adult FM carried out within the same surgical
team.
In 2005, Chen and colleagues5,6 published their own
experience of ECMO in patients with FM and compared it
with data on use of BIVADs from the literature. They
described a group of 15 patients for whom the mean time
of assistance on ECMO was 5.7  3.1; the neurologic
complication rate was 6.7%, and the re-exploration rate
for hemostasis was 8.9%. Global survival was 73.3%.
They concluded their results were better than those pub-
lished on BIVADs in the literature and considered ECMO
to be the first-line mechanical circulatory support treatment
in patients with FM with profound shock when IABCP is
inadequate or infeasible.gery c January 2009
Pages et al Evolving Technology
E
TAcker,2 in 2001, reviewed the literature comparing differ-
ent types of mechanical support in adults with FM: ECMO,
left ventricular assist device (Abiomed, Danvers, Mass;
Thoratec; Thermo Cardiosystems, Woburn, Mass; and
Novacor, World Heart, Inc, Oakland, Calif), and BIVAD
(Abiomed and Thoratec). The highest survival rate was
reported with the BIVAD, leading to either recovery or
transplantation in 70% of the patients. In our series we
report the same survival rate as Acker with both the BIVAD
and ECMO systems; one can assume that this is in part due
to the fact that we could achieve the same blood flow. More-
over, we found a significantly lower rate of RBCU transfu-
sions associated with ECMO. Furthermore, duration of
assistance, infectious complication rate (especially in pa-
tients who has an ECMO device installed after achieving
local anesthesia), and renal and hepatic dysfunctions tended
to be less in our ECMO group patients.
The short duration of support in patients undergoing
ECMO can be explained by the fact that it is easier to
make a decision to remove an ECMO device than a BIVAD.
Furthermore, femorofemoral ECMO can be set up easily
outside of a cardiac surgery center (after achievement of
local anesthesia or not) and allows secondary transfer, as
we experienced for our 2 patients. This ability to transfer
was already described by McBride and associates7 in
2000, who underlined that patients could be moved between
clinical centers with acceptable risks. This technique allows
supporting patients who would have died otherwise. More-
over, because ECMO can be set up under local anesthesia
and can provide simultaneous oxygenation, orotracheal intu-
bation is not necessarily required. This permits better pulmo-
nary outcome: no pneumonia was observed in patients with
ECMO devices implanted after achievement of local anes-
thesia versus 100% of patients who underwent implantation
of a mechanical support device under orotracheal intubation
(BIVAD or ECMO).
Finally, in case of persistent low outflow with femorofe-
moral ECMO, we think, in opposition to some authors,8The Journal of Thoracic andthat shifting to a central ECMO system is more simple
and less invasive than shifting to a BIVAD. Finaly ECMO
is less costly (Disposable material is 24 times cheaper for
ECMO in comparison to BIVAD in our experience).
CONCLUSION
ECMO is as efficient as a BIVAD in supporting adult
patients with FM related to cardiogenic shock. ECMO facil-
itates quick recovery of renal and hepatic function. More-
over, it shows several advantages: red blood cell saving,
possibility of local anesthesia for set up and removal, mobil-
ity of surgical teams for installation, and safety of secondary
transfer. In conclusion, femorofemoral ECMO is the best
first-line treatment in FM in adults, with central ECMO as
a second-line treatment.
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